Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
119-hr-3873119th Congress
KO Cancer Act
Sponsored By: Representative Fitzpatrick, Brian K. [R-PA-1]
Introduced
Summary
Would create a new dedicated funding stream for the National Cancer Institute. It would also require HHS and the FDA to study cancer drug shortages and deliver recommendations within one year.
Show full summary
- Families and patients: Would expand resources for cancer research by establishing an annual appropriation equal to 25% of the NCI's fiscal year 2022 appropriation for fiscal years 2026–2030.
- Researchers and institutions: The new funds would come from Treasury amounts not otherwise appropriated, be available until expended, and would be in addition to other NCI funding.
- Regulators and drug makers: Would require HHS, acting through the FDA, to study economic causes, supply-chain failures, development and approval delays, and shortages of generics and biosimilars, then report findings and recommendations to Congress within one year.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More funding for National Cancer Institute
If enacted, the bill would give the National Cancer Institute extra money each year from 2026 to 2030. Each year’s amount would equal 25% of the Institute’s 2022 appropriation. The money would come from the Treasury, stay available until spent, and be on top of regular funding. The Institute would use it for cancer research grants and contracts. Patients and families could benefit later as research improves care.
Sponsors & CoSponsors
Sponsor
Fitzpatrick, Brian K. [R-PA-1]
PA • R
Cosponsors
Rep. Dingell, Debbie [D-MI-6]
MI • D
Sponsored 6/10/2025
Rep. Vasquez, Gabe [D-NM-2]
NM • D
Sponsored 7/25/2025
Rep. Gottheimer, Josh [D-NJ-5]
NJ • D
Sponsored 8/22/2025
Rep. Vindman, Eugene Simon [D-VA-7]
VA • D
Sponsored 9/15/2025
Rep. Bresnahan, Robert P. [R-PA-8]
PA • R
Sponsored 9/30/2025
Rep. Gillen, Laura [D-NY-4]
NY • D
Sponsored 10/10/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov